Hypernatraemia and diuretics
- Conditions
- Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]Intensive Care admissionsodium level in plasma > 142 mmol/L
- Registration Number
- EUCTR2013-002165-19-NL
- Lead Sponsor
- Medical Center Leeuwarden
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
admission in the intensive care
age > 18 years
sodium level in plasma > 142 mmol/L
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 30
Exclusion Criteria
sodium level > 142 mmol/L before admission
no informed consent
diabetes insipidus
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To establish whether captopril / hydrochloorthiazide is able to reduce hypernatraemia in intensive care patients;Secondary Objective: To establish whether captopril / hydrochloorthiazide is able to reduce the timperiod of hypernatraemia in intensive care patients;Primary end point(s): 5 points decrease of sodium level in plasma in mmol/L;Timepoint(s) of evaluation of this end point: 7 days
- Secondary Outcome Measures
Name Time Method Secondary end point(s): decrease of duration of hypernatraemia;Timepoint(s) of evaluation of this end point: 7 days